The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best up and coming stocks with highest upside potential. On March 23, Abivax reported its full-year 2025 financial results, highlighting steady clinical progress for its lead drug candidate, obefazimod. Following a major $700.3 million public offering in July 2025, the company ended the year with €530.4 million in cash and short-term investments. This liquidity provides a projected cash runway into Q4 2027, allowing Abivax to fully fund its pivotal trials and prepare for potential commercialization.

Operationally, the company’s Phase 3 ABTECT-UC maintenance trial for ulcerative colitis remains the primary focus. An independent safety review in March confirmed no new safety signals, with nearly 90% of patients having completed the 44-week treatment period. Topline results from this trial are expected in late Q2 2026, with a potential NDA submission targeted for Q4 2026, contingent on positive data.

To lead its transition from a clinical-stage to a commercial-stage entity, Abivax made several high-profile leadership appointments, most notably naming Michael Nesrallah as Chief Commercial Officer. Nesrallah brings deep expertise in the inflammatory bowel disease/IBD market from his previous tenure at Takeda. While the company reported a net loss of €336.1 million for 2025 (largely driven by increased R&D and non-cash expenses related to its share price appreciation) the retirement of its senior convertible notes and other debt tranches has simplified the balance sheet for the next phase of growth.

ABIVAX Société Anonyme (NASDAQ:ABVX) develops therapeutics targeting chronic inflammatory diseases.

While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.